iCAD announced the commercial availability of its ProFound AI for breast cancer detection in digital breast tomosynthesis in 2018, which delivers critical benefits, including improvements of cancer detection rates, a decrease in unnecessary patient recalls, and shorter reading times for radiologists.
"We envision the field of mammography moving from age-based screening protocols to "risk adaptive screening." Concurrently, we foresee the emergence of individualized breast screening protocols based on risk characteristics," said Mike Klein, Executive Chairman and CEO of iCAD. "This new frontier of predictive risk assessment for cancer is indicative of the continued expansion of our newly released ProFound AI offering for breast cancer detection. Correlating iCAD's high cancer detection rates, low false positive levels and a 50% reduction in reading time with the burgeoning volume of patent risk data, may provide a quantum leap in clinical efficacy and patient care.
Ad Statistics
Times Displayed: 50697
Times Visited: 1465 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
We are extremely pleased to have the opportunity to partner with researchers from one of the most prestigious medical institutes in the world. The fusion of research from Karolinska Institute with iCAD's advanced AI capability has the potential to transform breast disease management. We envision that novel AI technology will further evolve the clinician and patient interface to a proactive disease management approach where prediction, and possibly even prevention, become a part of the clinical dialogue."
On Friday, March 1st at the European Congress of Radiology in Vienna, Austria, iCAD will host AI After Dark, an evening reception titled "New Frontier: Predicting Breast Cancer through AI." The event will feature industry leaders in breast health who will discuss their perspectives on how the industry is transforming breast cancer detection, and share their personal experiences with ProFound AI in research and clinical practice. In addition, Dr. Hall will discuss Karolinska's collaborative approach to a "risk stratified approach to breast cancer screening."
For more information about iCAD and its solutions or to register for a meeting or demonstration at ECR, please visit www.icadmed.com/ecr2019.html.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Back to HCB News
